Goldman Sachs
IOVA icon

Goldman Sachs’s Iovance Biotherapeutics IOVA Stock Holding History

Goldman Sachs’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-160,000
Closed -$1.18M – 6238
2024
Q4 		$1.18M Buy
+160,000
New +$1.48M ﹤0.01% 4689
2022
Q1 		– Sell
-22,200
Closed -$424K – 6725
2021
Q4 		$424K Buy
+22,200
New +$489K ﹤0.01% 5477
2021
Q3 		– Sell
-40,000
Closed -$1.04M – 6354
2021
Q2 		$1.04M Buy
+40,000
New +$1.04M ﹤0.01% 4726
2020
Q1 		– Sell
-29,100
Closed -$805K – 5376
2019
Q4 		$805K Buy
+29,100
New +$662K ﹤0.01% 4245
2018
Q1 		– Sell
-5,200
Closed -$42K – 6133
2017
Q4 		$42K Sell
5,200
-3,200
-38% -$25.7K ﹤0.01% 5972
2017
Q3 		$65K Buy
8,400
+7,500
+833% +$47.5K ﹤0.01% 6197
2017
Q2 		$7K Sell
900
-600
-40% -$3.81K ﹤0.01% 6675
2017
Q1 		$11K Sell
1,500
-3,600
-71% -$26.4K ﹤0.01% 6604
2016
Q4 		$35K Buy
5,100
+3,300
+183% +$22.7K ﹤0.01% 6482
2016
Q3 		$15K Buy
+1,800
New +$15.2K ﹤0.01% 6816
2016
Q2 		– Sell
-410,800
Closed -$2.09M – 7130
2016
Q1 		$2.09M Buy
410,800
+409,900
+45,544% +$2.24M ﹤0.01% 3427
2015
Q4 		$7K Sell
900
-2,200
-71% -$15.3K ﹤0.01% 7016
2015
Q3 		$18K Buy
+3,100
New +$24.1K ﹤0.01% 7051

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs's IOVA Position: Q1 2026 in Review

Goldman Sachs increased its Iovance Biotherapeutics (IOVA) stake by 1.8% in Q1 2026, buying an estimated $488K and bringing the position to 8,760,060 shares worth $30.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2034.

Goldman Sachs first reported a position in IOVA in Q1 2015 and has held it in 44 quarters since. The position peaked at $60.7M in Q1 2021. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Goldman Sachs held 8,760,060 shares of Iovance Biotherapeutics worth $30.7M as of Q1 2026.
  • Goldman Sachs bought 152,496 Iovance Biotherapeutics shares in Q1 2026, an estimated $488K.
  • Iovance Biotherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2034 holding.
  • Goldman Sachs first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 44 quarters since.
  • Goldman Sachs's Iovance Biotherapeutics position peaked at $60.7M in Q1 2021.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.